Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of <i>KRAS</i> <i>p.G12C</i> inhibitors in advanced NSCLC: A systematic review and meta-analysis.
e20691 Background: Advances in target therapy have improved the natural history of non-small-cell lung cancer (NSCLC). KRAS pG12C...
Assessing interest and satisfaction with integrative oncology approaches among hospitalized patients.
e23247 Background: Many integrative oncology (IO) outpatient (OP) cancer care approaches—yoga, acupuncture, massage, physical activity—have demonstrated b...
Effect of human-AI teams on oncology prescreening: Final analysis of a randomized trial.
1508 Background: Eligibility assessment for oncology clinical trials – “prescreening” – relies on manual review of unstruc...
Multimodal evaluation of metabolic dysfunction–associated steatotic liver disease (MASLD)–related biliary tract cancer (BTC) and immunotherapy outcomes.
4091 Background: Rising incidence of BTC, particularly intrahepatic cholangiocarcinoma (iCCA), may be linked to increasing incidence of obesity, MASLD and...
A phase 1 trial of the FACT inhibitor CBL0137 in pediatric patients with relapsed or refractory solid and CNS tumors: A report from the Children’s Oncology Group study PEPN2111.
10051 Background: CBL0137 is a novel agent that targets the FAcilitates Chromatin Transcription complex (FACT), a histone chaperone that regulates chromat...
Quality-adjusted time without symptoms of disease or toxicity (Q-TWiST) analysis of pembrolizumab (pembro) versus chemotherapy (chemo) in microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) metastatic colorectal cancer (mCRC) in the KEYNOTE-177 trial.
3631 Background: In KEYNOTE-177 (NCT02563002),first-line pembro provided significantly longer progression-free survival and a trend toward improvement in...
The effect of metformin exposure on colorectal cancer incidence according to tumor sidedness.
10523 Background: Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality. Tumor sidedness influences treatment decisions due...
Comprehensive profiling of circulating tumor DNA and microbial landscapes in nasopharyngeal cancer across Asia: NCCH1905/A-TRAIN study.
6051 Background: Nasopharyngeal cancer (NPC), a malignancy of the nasopharynx, is strongly associated with Epstein-Barr virus (EBV) infection. Although ra...
Impact of <i>TP53</i> mutations and variant allelic frequency on survival in adults with newly diagnosed acute lymphoblastic leukemia.
6544 Background: TP53 mutations are associated with poor outcomes in acute lymphoblastic leukemia (ALL); however, a variant allele frequency (...
Biomarkers of emergent resistance to sotorasib plus panitumumab in <i>KRAS</i> G12C-mutated metastatic colorectal cancer (mCRC) from the randomized, phase 3 CodeBreaK 300 study.
3540 Background: The use of sotorasib (soto; KRAS G12C inhibitor) alone in patient...
Real-world comparison of neoadjuvant chemoimmunotherapy with chemotherapy in muscle-invasive bladder cancer.
e16549 Background: Muscle-invasive bladder cancer (MIBC) continues to pose a significant health challenge, as conventional neoadjuvant chemotherapy (NAC)...
Precemtabart tocentecan (M9140), an anti-CEACAM5 ADC with exatecan payload, in patients with metastatic colorectal cancer (mCRC): Results from the dose optimization of the phase 1 PROCEADE CRC-01 study.
3038 Background: CEACAM5 is overexpressed in ~90% of CRCs, with limited expression on healthy cells. Precemtabart tocentecan (M9140), the first anti-CEACA...
Cytomolecular mechanisms of relapse after frontline FLT3 inhibitor (FLT3i)-based therapy in FLT3-mutated (mut) acute myeloid leukemia (AML).
6539 Background: Data regarding the mechanisms of relapse and outcomes with salvage therapies in patients (pts) with FLT3 mut AML...
Towards personalized management of intraductal papillary mucinous neoplasms with multimodal artificial intelligence.
e16461 Background: According to the Fukuoka and Kyoto consensus guidelines, the clinical management of pancreatic intraductal papillary mucinous neoplasms...
Interplatform and cross-cohort meta-analysis of tumor transcriptomics to predict non-small cell lung cancer c-Met protein overexpression.
e15164 Background: Antibody-drug conjugate (ADC) antigen target expression is a key predictive biomarker of patients’ (pts) treatment response. Convention...
Effect of CD4+PD-1+CXCR6+ T cells on the response of immune checkpoint inhibitor therapy in brain metastases of NSCLC.
2028 Background: Brain metastases (BrM) in non-small cell lung cancer (NSCLC) presented a significant challenge due to poor prognosis. While immune checkp...
Onkoras-101: A phase 1a/1b open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of BBO-8520 in subjects with advanced KRAS <sup>G12C</sup> mutant non-small-cell lung cancer.
TPS8649 Background: BBO-8520 is a first-in-class, potent, selective, directly binding, orally bioavailable, covalent inhib...
Beyond study cohorts: Visualizing patient experience informed by patient-reported outcomes (PROs) deployed in multiple myeloma clinical practice.
e23207 Background: Integrating PROs into oncology care has been proven to enhance patient outcomes and reduce health resource utilization. While PRO trend...
Benchmarking clinical reasoning and accuracy of large language models on breast oncology multiple-choice questions.
e13637 Background: Large language models (LLMs) like GPT-4 (OpenAI) and Claude Opus (Anthropic) showed high accuracy in medical multiple-choice exams, but...
Effect of armed oncolytic adenovirus on immunotherapy for primary and metastatic brain tumors.
2048 Background: Oncolytic viruses have shown promise in clinical trials for solid tumors, including glioma and melanoma, but only a subset of patients be...
30 year trends in racial disparities for early stage lung cancer treatment.
1599 Background: Racial disparities in lung cancer treatment have been recognized for over 30 years. Our prior work showed that among Medicare beneficiari...
Murine metastatic embryonal rhabdomyosarcoma survival and immune response with a total tumor RNA lipid particle aggregate vaccine.
e14646 Background: Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma (STS) requiring intense multiagent chemotherapy in conjunction...
Ocular toxicities observed in polypeptide vaccine trials for melanoma.
e14643 Background: Peptide vaccines are a promising approach for melanoma treatment. They are generally well-tolerated but a subset of patients developed...
Trends in racial and gender diversity among adult hemato-oncology trainees over last decade and impact of Covid.
9011 Background: We aim to examine trends in racial and gender diversity of trainees within adult and pediatrics hemato-oncology (H-0) fellowships, and ev...
Real-life use of G-CSF in patients with small cell lung cancer (SCLC): Secondary data analysis from the French national cohorts KBP-ESCAP-2020-CPHG.
e24115 Background: Febrile neutropenia (FN) is a frequent related side-effect in the treatment of lung cancer (LC), a common and potentially life-threaten...